Collegium Pharmaceutical Stock Analysis

Collegium Stock Analysis Notes

About 98.0% of the company shares are held by institutions such as insurance companies. The company had not issued any dividends in recent years. Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts. Collegium Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 152 people. For more info on Collegium Pharmaceutical please contact Vikram Karnani at 781 713 3699 or go to https://www.collegiumpharma.com.

Collegium Pharmaceutical Investment Alerts

Collegium Largest EPS Surprises

View All Earnings Estimates

Collegium Pharmaceutical Environmental, Social, and Governance (ESG) Scores

Collegium Stock Institutional Investors

Note, although Collegium Pharmaceutical's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Collegium Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.45 B.

Collegium Profitablity

The company has Profit Margin (PM) of 0.08 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.32 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.32.

Management Efficiency

Collegium Pharmaceutical has return on total asset (ROA) of 0.0675 % which means that it generated a profit of $0.0675 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2296 %, meaning that it created $0.2296 on every $100 dollars invested by stockholders. Collegium Pharmaceutical's management efficiency ratios could be used to measure how well Collegium Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is expected to rise to 0.11 this year. Return On Capital Employed is expected to rise to 0.14 this year. At this time, Collegium Pharmaceutical's Intangible Assets are quite stable compared to the past year. Return On Tangible Assets is expected to rise to 0.11 this year, although the value of Net Tangible Assets are projected to rise to (432.9 M).

Technical Drivers

As of the 16th of February 2026, Collegium Pharmaceutical shows the Risk Adjusted Performance of 0.0433, mean deviation of 1.61, and Downside Deviation of 2.43. Collegium Pharmaceutical technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Collegium Pharmaceutical downside deviation, jensen alpha, as well as the relationship between the Jensen Alpha and downside variance to decide if Collegium Pharmaceutical is priced correctly, providing market reflects its regular price of 45.79 per share. Given that Collegium Pharmaceutical has jensen alpha of 0.0489, we suggest you to validate Collegium Pharmaceutical's prevailing market performance to make sure the company can sustain itself at a future point.

Collegium Pharmaceutical Price Movement Analysis

Collegium Pharmaceutical Insider Trading Activities

Collegium Pharmaceutical Outstanding Bonds

Collegium Pharmaceutical Predictive Daily Indicators

Collegium Pharmaceutical Corporate Filings

Collegium Pharmaceutical Forecast Models

Collegium Pharmaceutical's time-series forecasting models are one of many Collegium Pharmaceutical's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Collegium Pharmaceutical's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Collegium Pharmaceutical Bond Ratings

Collegium Pharmaceutical financial ratings play a critical role in determining how much Collegium Pharmaceutical have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Collegium Pharmaceutical's borrowing costs.

Collegium Pharmaceutical Debt to Cash Allocation

Collegium Pharmaceutical currently holds 859.3 M in liabilities with Debt to Equity (D/E) ratio of 3.82, implying the company greatly relies on financing operations through barrowing. Collegium Pharmaceutical has a current ratio of 0.97, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Collegium Pharmaceutical's use of debt, we should always consider it together with its cash and equity.

Collegium Pharmaceutical Total Assets Over Time

Collegium Pharmaceutical Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Collegium Pharmaceutical uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Collegium Pharmaceutical Debt Ratio

50.0

It seems Collegium Pharmaceutical uses both, debt and equity to finance its assets. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Collegium Pharmaceutical's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Collegium Pharmaceutical, which in turn will lower the firm's financial flexibility.

Collegium Pharmaceutical Corporate Bonds Issued

Collegium Short Long Term Debt Total

Stock analysis is the technique used by a trader or investor to examine and evaluate how Collegium Pharmaceutical prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Collegium shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Collegium Pharmaceutical. By using and applying Collegium Stock analysis, traders can create a robust methodology for identifying Collegium entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Collegium analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Collegium analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Collegium Pharmaceutical stock analysis indicators help investors evaluate how Collegium Pharmaceutical stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Collegium Pharmaceutical shares will generate the highest return on investment. By understating and applying Collegium Pharmaceutical stock analysis, traders can identify Collegium Pharmaceutical position entry and exit signals to maximize returns.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collegium Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

It's important to distinguish between Collegium Pharmaceutical's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Collegium Pharmaceutical should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Collegium Pharmaceutical's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.